However, no significant phenotypic differences were observed between the residual CD8+ TCR-Vβ− populations in T-LGLL patients and the residual CD8+ TCR-Vβ− populations in dasatinib-treated CML patients (Fig. 3B, bottom panel). This evidence concerns the gene CD8A and chronic myelogenous leukemia, BCR-ABL1 positive.